Physician profile
Benjamin Medalion
NPI 1437590528
$5,530.53
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $5,001 · 2020: $408 · 2022: $121.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,949.71 | 2019-2020 | |
| Abiomed | $1,475.84 | 2019-2020 | |
| Medtronic Vascular, INC. | $815.20 | 2019-2020 | |
| Bolton Medical INC | $120.73 | 2022 | |
| Quest Medical INC. | $44.55 | 2020 | |
| Livanova USA, INC. | $28.47 | 2019 | |
| Baxter Healthcare | $27.65 | 2019 | |
| Atricure, INC. | $24.13 | 2019 | |
| Avanos Medical | $17.77 | 2019 | |
| Getinge USA Sales, LLC | $13.49 | 2019 | |
| Zimmer Biomet Holdings, INC. | $12.99 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Research and ownership
$800.31 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Medalion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.